Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Citigroup Inc.

Citigroup Inc. lowered its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 14.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 145,608 shares of the medical equipment provider’s stock after selling 25,334 shares during the quarter. Citigroup Inc. owned 0.07% of Zimmer Biomet worth $14,342,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Key Financial Inc boosted its position in shares of Zimmer Biomet by 164.6% during the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 163 shares in the last quarter. Cullen Frost Bankers Inc. lifted its stake in Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 116 shares during the last quarter. Root Financial Partners LLC bought a new stake in Zimmer Biomet during the third quarter worth approximately $31,000. Cary Street Partners Investment Advisory LLC grew its position in Zimmer Biomet by 83.7% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 149 shares during the last quarter. Finally, Mather Group LLC. bought a new position in shares of Zimmer Biomet in the third quarter valued at $36,000. 88.89% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wall Street Zen lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. UBS Group reiterated a “sell” rating and issued a $89.00 price target on shares of Zimmer Biomet in a research report on Wednesday, February 11th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Tuesday, February 10th. Johnson Rice set a $112.00 price objective on shares of Zimmer Biomet in a research note on Wednesday, November 5th. Finally, BTIG Research reiterated a “buy” rating and issued a $112.00 target price on shares of Zimmer Biomet in a report on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, ten have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $106.20.

Zimmer Biomet Stock Performance

ZBH stock opened at $98.42 on Friday. The firm has a 50 day simple moving average of $91.52 and a 200 day simple moving average of $95.95. Zimmer Biomet Holdings, Inc. has a 52 week low of $84.59 and a 52 week high of $114.44. The stock has a market cap of $19.25 billion, a P/E ratio of 27.80, a P/E/G ratio of 2.06 and a beta of 0.62. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company had revenue of $2.24 billion during the quarter, compared to analyst estimates of $2.22 billion. During the same quarter last year, the business posted $2.31 EPS. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is 27.12%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.